A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2017
At a glance
- Drugs IMM-201 (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms DAR-PIA
- 23 Mar 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 23 Mar 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.
- 23 Mar 2017 Status changed from recruiting to active, no longer recruiting.